RE:Off Topic - how much does Evergrande own in Canada?
Also "off topic" - below is a partial list of "references" that Cytodyn has on their patent application for their main drug Leronlimab for which they are trying to get emergency use authorization to be used against Covid-19. Do you think they are getting the run around in the U.S.? In the meantime they have now set up studies in Brazil and Philippines because of hurdles being put up by the U.S. FDA. Do they call it bureaucracy? It's tough for small applicants. Big pharma at work??
Chen et al., "Functional roles of CCL5/RANTES in liver disease," Liver Research 4:28-34, 2020. cited by applicant .
Chen et al., "Response of Memory CD8.sup.+ T Cells to Severe Acute Respiratory Syndrome (SARS) Coronavirus in Recovered SARS Patients and Healthy Individuals," The Journal of Immunology 175:591-598, 2005. cited by applicant .
Chothia et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins," J. Mol. Biol. 196:901-917, 1987. cited by applicant .
CytoDyn Inc., "Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7," Press Release, Apr. 9, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Collaborating with U.K.'s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients," Press Release, Apr. 7, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks," Press Release, Apr. 1, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation," Press Release, Mar. 27, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)," Press Release, Mar. 9, 2020. (5 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)," Press Release, Mar. 8, 2020. (5 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) and Advises Correction to Press Release Issued on Mar. 12, 2020," Press Release, Mar. 16, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries," Press Release, Apr. 30, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19," Press Release, May 15, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-arm Comparative and Combination Trial of Leronlimab and Remdesivir," Press Release, May 18, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus--CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S.--CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May," Press Release, May 4, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "FDA Clears CytoDyn's Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately," Press Release, Mar. 31, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19," Press Release, Apr. 15, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated," Press Release, Apr. 6, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation," Press Release, Mar. 27, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Manuscript Describes How CytoDyn's Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients," Press Release, May 6, 2020. (5 pages). cited by applicant .
CytoDyn Inc., "Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn's Leronlimab" Press Release, Apr. 7, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Novant Health Initiates Phase 2b/3 Trial with CytoDyn's Leronlimab for Severely and Critically Ill COVID-19 Patients," Press Release, May 7, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn's Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab and Discharged from Hospital," Press Release, Apr. 9, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged," Press Release, Apr. 13, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients," Press Release, Mar. 30, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients," Press Release, Apr. 2, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn's Leronlimab, Bringing the Total to Four Patients," Press Release, Mar. 23, 2020. (4 pages). cited by applicant .
CytoDyn Inc., "U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn's Leronlimab," Press Release, Mar. 19, 2020. (4 pages). cited by applicant .
Dhody et al., "PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection," HIV Clin. Trials 19(3):85-93, 2018. cited by applicant .
Dr. Yo, "Is LERONLIMAB A Game Changer? Coronavirus (COVID-19) Treatment | How does LERONLIMAB Work?," YouTube Video, May 1, 2020, URL=https://www.youtube.com/watch?v=OW6IxELNtj4&feature=youtu.be, 3 pages. (Screenshot). cited by applicant .
Dunbar et al., "ANARCI: antigen receptor numbering and receptor classification," Bioinformatics 32(2):298-300, 2016. cited by applicant .
Evaluate, "Human Genome Sciences Characterizes Panel of Novel Human Monoclonal Antibodies That Specifically Antagonize the CCR5 Receptor and Block HIV-1 Entry," Press Release, Nov. 2, 2004. (1 page). cited by applicant .
Glass et al., "Functional analysis of the CC chemokine receptor 5 (CCR5) on virus-specific CD8.sup.+ T cells following coronavirus infection of the central nervous system," Virology 312:407-414, 2003. cited by applicant .